Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers

A. Zouhair; M. Ozsahin; M. Schaffer; S. Albrecht; F. Camus; P. Jichlinski; R. O. Mirimanoff; A. Bischof Delaloye; J. Y. Meuwly; J. O. Prior

doi:10.2174/092986710791556014

Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers

A. Zouhair
, M. Ozsahin
, M. Schaffer
, S. Albrecht
, F. Camus
, P. Jichlinski
, R. O. Mirimanoff
, A. Bischof Delaloye
, J. Y. Meuwly
, J. O. Prior

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.

Original language	English
Pages (from-to)	2492-2502
Number of pages	11
Journal	Current Medicinal Chemistry
Volume	17
Issue number	23
DOIs	https://doi.org/10.2174/092986710791556014
State	Published - 20 Aug 2010
Externally published	Yes

Keywords

F-18-fluorodeoxyglucose
Prostate cancer
bladder cancer
positron emission tomography
testicular cancer

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery
Organic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/092986710791556014

Cite this

@article{ac408be279d1420f9a96e1db92934e03,

title = "Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers",

abstract = "Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.",

keywords = "F-18-fluorodeoxyglucose, Prostate cancer, bladder cancer, positron emission tomography, testicular cancer",

author = "A. Zouhair and M. Ozsahin and M. Schaffer and S. Albrecht and F. Camus and P. Jichlinski and Mirimanoff, \{R. O.\} and \{Bischof Delaloye\}, A. and Meuwly, \{J. Y.\} and Prior, \{J. O.\}",

year = "2010",

month = aug,

day = "20",

doi = "10.2174/092986710791556014",

language = "English",

volume = "17",

pages = "2492--2502",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers",

number = "23",

}

TY - JOUR

T1 - Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers

AU - Zouhair, A.

AU - Ozsahin, M.

AU - Schaffer, M.

AU - Albrecht, S.

AU - Camus, F.

AU - Jichlinski, P.

AU - Mirimanoff, R. O.

AU - Bischof Delaloye, A.

AU - Meuwly, J. Y.

AU - Prior, J. O.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.

AB - Positron emission computed tomography (PET) is a functional, noninvasive method for imaging regional metabolic processes that is nowadays most often combined to morphological imaging with computed tomography (CT). Its use is based on the well-founded assumption that metabolic changes occur earlier in tumors than morphologic changes, adding another dimension to imaging. This article will review the established and investigational indications and radiopharmaceuticals for PET/CT imaging for prostate cancer, bladder cancer and testicular cancer, before presenting upcoming applications in radiation therapy.

KW - F-18-fluorodeoxyglucose

KW - Prostate cancer

KW - bladder cancer

KW - positron emission tomography

KW - testicular cancer

UR - https://www.scopus.com/pages/publications/77955627956

U2 - 10.2174/092986710791556014

DO - 10.2174/092986710791556014

M3 - Article

C2 - 20491646

AN - SCOPUS:77955627956

SN - 0929-8673

VL - 17

SP - 2492

EP - 2502

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

IS - 23

ER -

Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this